Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (1), e000342

Global Consensus Building and Prioritisation of Fundamental Lupus Challenges: The ALPHA Project


Global Consensus Building and Prioritisation of Fundamental Lupus Challenges: The ALPHA Project

Susan Manzi et al. Lupus Sci Med.


Objective: Lupus is a complex, heterogeneous autoimmune disease that has yet to see significant progress towards more timely diagnosis, improved treatment options for short-term and long-term outcomes, and appropriate access to care. The Addressing Lupus Pillars for Health Advancement (ALPHA) project is the first step in establishing global consensus and developing concrete strategies to address the challenges limiting progress.

Methods: A Global Advisory Committee of 13 individuals guided the project and began barrier identification. Seventeen expert interviews were conducted to further characterise key barriers. Transcripts were analysed using Nvivo and a codebook was created containing a list of thematic 'nodes' (topics) and their descriptions. Findings were used to develop a final survey instrument that was fielded to a diverse, international stakeholder audience to achieve broad consensus.

Results: Expert interviews identified lupus heterogeneity as the primary barrier hindering advancement. Subsequent barriers were categorised into three areas: (1) Drug development. (2) Clinical care. (3) Access and value. The global survey received 127 completed responses from experts across 20 countries. Respondents identified barriers as high priority including the lack of biomarkers for clinical and drug development use, flawed clinical trial design, lack of access to clinicians familiar with lupus, and obstacles to effective management of lupus due to social determinants of care. Respondents also identified 30 autoimmune conditions that may be lupus-related based on overlapping features, shared autoantibodies and pathophysiology.

Conclusions: ALPHA is a comprehensive initiative to identify and prioritise the continuum of challenges facing people with lupus by engaging a global audience of lupus experts. It also explored views on lupus as a spectrum of related diseases. Conclusions from this effort provide a framework to generate actionable approaches to the identified high-priority barriers.

Keywords: barriers to clinical care; clinical trial design; drug development; heterogeneity; lupus; patient access.

Conflict of interest statement

Competing interests: IB is an NIHR Senior Investigator and is funded by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. IB has received grants and/or honoraria and/or consultancy fees from Genzyme Sanofi, GSK, UCB, AstraZeneca, Medimmune, Eli Lilly, Merck Serono and ILTOO. KC receives research support to study lupus from the NIH (R01 AR057327 and K24 AR066109), Merck and AstraZeneca. KC has received consulting honoraria < $5000 from AstraZeneca. TD has received grants for study conduct and/or honoraria and /or consultancy fees from Janssen, GSK, Roche/Genentech, Eli Lilly, UCB, Merck Serono, AbbVie and Boston Pharmaceuticals. SM has received grants and/or honoraria and/or consultancy fees from Exagen Diagnostics, GSK, UCB and AstraZeneca. EM has received grants for study conduct and/or honoraria and/or consultancy fees from AbbVie, Sanofi, GSK, UCB, AstraZeneca, Eli Lilly, Merck Serono and Janssen. BR has received grants and/or honoraria and/or consultancy fees from Aurinia, EMD Serono, Janssen and MedImmune. BR is also a Principal Investigator on research projects for EMD Serono Research and Development Institute Inc. (Collaborated by Merck KGaA); Human Genome Sciences Inc, a GSK Company; NIH and RILITE Foundation. LES receives research support from CARRA and PCORI. LES is also on Data and Safety Monitoring Boards for UCB and Sanofi. VPW has received grants and/or honoraria from Celgene, Janssen, Biogen, Gilead, Viela, Medimmune, Pfizer, Resolve, AstraZeneca, Kyowa Hakko Kirin, Eli Lilly.

Similar articles

See all similar articles


    1. Yen EY, Singh RR. Brief report: Lupus-An unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol 2018;70:1251–5. 10.1002/art.40512 - DOI - PMC - PubMed
    1. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 2018;30:144–50. 10.1097/BOR.0000000000000480 - DOI - PMC - PubMed
    1. Singh RR, Yen EY. Sle mortality remains disproportionately high, despite improvements over the last decade. Lupus 2018;27:1577–81. 10.1177/0961203318786436 - DOI - PMC - PubMed
    1. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605–20. 10.1038/nrrheum.2016.137 - DOI - PubMed
    1. Agarwal N, Kumar V. Burden of lupus on work: issues in the employment of individuals with lupus. Work 2016;55:429–39. 10.3233/WOR-162398 - DOI - PubMed

LinkOut - more resources